Data / Form D filings / Humacyte, Inc.
Humacyte, Inc.: Form D filings
Humacyte, Inc., a biotechnology company in Durham, NC, filed 7 Form D notices with the SEC between 2009 and 2018. The latest, on June 26, 2018, reports $150 million sold of a $150 million offering to 1 investor.
Find out what Humacyte, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2525 E. NC HIGHWAY 54, Durham, NC, 27713
- Phone
- (919) 313-9633
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1385943
The full lists. Form D filings in North Carolina: 984 rows, $49.20, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jun 26, 2018 | New notice | $150,000,000 | $150,000,000 | $0 | 1 | Jun 25, 2018 | sec.gov |
| Mar 9, 2018 | New notice | $75,000,000 | $74,999,980 | $20 | 29 | Feb 23, 2018 | sec.gov |
| Jan 20, 2015 | Amendment | $73,762,373 | $49,762,373 | $24,000,000 | 6 | Oct 1, 2007 | sec.gov |
| Jan 21, 2014 | Amendment | $49,100,000 | $37,262,373 | $11,837,627 | 6 | Oct 1, 2007 | sec.gov |
| Apr 9, 2012 | Amendment | $27,000,000 | $22,000,000 | $5,000,000 | 2 | Oct 1, 2007 | sec.gov |
| Sep 2, 2010 | Amendment | $12,000,000 | $12,000,000 | $0 | 1 | Oct 1, 2007 | sec.gov |
| Nov 23, 2009 | Amendment | $7,000,000 | $7,000,000 | $0 | 1 | Oct 1, 2007 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Jeffrey H. Lawson | Executive Officer | |
| Paul A. Boyer | Executive Officer | |
| Theodore D. Lithgow | Executive Officer | |
| Robert S. Langer | Director | |
| Dale A. Sander | Director | |
| Robert Anderson | Director | |
| Carrie S. Cox | Executive Officer, Director | |
| William H. Tente | Executive Officer | |
| Brady W. Dougan | Director | |
| Kathleen A. Sebelius | Director | |
| Laura E. Niklason | Director | |
| Max N. Wallace | Director |
Other biotechnology companies in North Carolina that filed recently
- Toggle Bio $200,000 · Oct 6, 2026
- Swift Cardiovascular, Inc. $810,000 · Sep 24, 2026
- Aclarity Genomics, Inc. $4.6 million · Sep 2, 2026
- Aer Therapeutics, Inc. $3 million · Aug 19, 2026
Every Form D from the week of Jun 25, 2018 · All recent filings in North Carolina · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Humacyte, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.